CCCC
C4 Therapeutics Inc
3.00$
-1.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
C4 Therapeutics Inc (CCCC) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -1.6 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | 37 | -7.9 | -10 | -17 | -15 | -14 | -22 | -25 | -18 | -18 | -26 | -27 | -22 | -28 | -29 | -33 | -19 | -31 | -24 | -18 | -5.0 | -24 | -18 | -33 | -12 | -31 | -22 | -30 | -1.6 | -85 | |
| 0.7 | 0.7 | 0.4 | 0.7 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 1.7 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.6 | 0.5 | 0.4 | 0.4 | 3.2 | 4.5 | |
| 0.1 | 0.1 | 0.6 | 0.7 | 0.1 | 0.2 | 0.4 | 2.7 | 3.8 | 5.2 | 6.1 | 6.4 | 8.9 | 8.1 | 6.0 | 6.9 | 6.3 | 6.4 | 8.2 | 6.4 | 6.2 | 6.4 | 8.8 | 8.2 | 5.5 | 5.0 | 4.6 | 4.0 | 2.7 | 3.0 | 14 | |
| – | – | 0.7 | 0.9 | 0.4 | 0.1 | 3.5 | 6.4 | 4.3 | 5.9 | 7.0 | 7.6 | 11 | 10 | 7.6 | 8.0 | 6.9 | 6.9 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 42 | 42 | 0.8 | -2.1 | -5.6 | -6.1 | 2.9 | -5.8 | -8.9 | -1.9 | -1.2 | -18 | -6.2 | -5.7 | -4.2 | -0.7 | -6.2 | 9.4 | -13 | 3.4 | 3.4 | 5.9 | -9.0 | 7.4 | -14 | 7.2 | -16 | -6.7 | -8.3 | 17 | -14 | |
| 0.6 | 0.6 | 0.1 | 0.1 | 0.2 | 0.1 | 0.3 | 0.3 | 0.4 | 0.7 | 0.1 | 0.1 | 0.2 | 0.5 | 3.3 | 1.5 | 0.6 | 0.4 | 0.6 | 0.2 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | 0.0 | 0.1 | 0.0 | 0.5 | |
| -8.1 | -8.1 | 15 | -0.2 | -0.2 | -104 | -32 | -54 | -62 | 32 | -101 | -59 | -4.0 | 33 | 20 | 9.3 | 54 | 15 | 58 | 32 | -53 | -12 | 0.2 | 14 | 29 | 39 | 4.1 | -81 | 16 | -15 | -75 | |
| 0.0 | 0.0 | 0.0 | 0.0 | – | -0.9 | -0.1 | 0.0 | 0.0 | – | 0.0 | 0.0 | – | – | – | – | -0.1 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | -0.1 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 | -0.2 | 0.0 | -0.2 | |
| – | – | 6.3 | 6.3 | 6.3 | 6.3 | 0.0 | 0.0 | – | – | – | – | – | – | -0.8 | -0.8 | -0.8 | -0.8 | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.2 | 152 | 2.5 | 194 | -0.2 | 171 | 0.6 | 0.5 | 0.5 | 0.3 | 0.4 | 0.0 | -0.7 | -0.7 | -11 | 58 | 35 | 0.1 | 11 | 0.1 | 0.0 | 0.0 | 7.8 | 119 | 0.5 | 34 | 161 | |
| 29 | 29 | 7.0 | 91 | -17 | 34 | -44 | 118 | -87 | 185 | -118 | -87 | -30 | 11 | -7.7 | -20 | 20 | -4.6 | 16 | 66 | -37 | -17 | -13 | -4.2 | -4.2 | 27 | -19 | 16 | -13 | 17 | 0.5 | |
| 36 | 36 | -8.0 | -10 | -17 | -14 | -15 | -22 | -25 | -19 | -18 | -26 | -27 | -23 | -31 | -31 | -34 | -19 | -31 | -24 | -18 | -5.2 | -24 | -18 | -33 | -12 | -32 | -22 | -30 | -1.6 | -85 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.